ストックスクリーナーアプリを入手
2.04
4.62%
0.09
プレマーケット:
2.01
-0.03
-1.47%
前日終値:
$1.95
開ける：
$1.95
24時間の取引高:
2.62M
Relative Volume:
1.08
時価総額：
$906.16M
収益：
$69.64M
当期純損益:
$-26.09M
株価収益率:
-28.53
EPS:
-0.0715
ネットキャッシュフロー:
$-38.80M
1週間 パフォーマンス:
+8.51%
1か月 パフォーマンス:
-8.52%
6か月 パフォーマンス:
+77.39%
1年 パフォーマンス:
+183.10%
1日の値動き範囲:
$1.95
$2.09
1週間の範囲:
$1.84
$2.09
52週間の値動き範囲:
$0.703
$2.53
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
名前
Lexicon Pharmaceuticals Inc
セクター
電話
(281) 863-3000
住所
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
2.04 | 870.62M | 69.64M | -26.09M | -38.80M | -0.0715 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-05 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-30 | 開始されました | Leerink Partners | Outperform |
| 2023-03-07 | 開始されました | Jefferies | Hold |
| 2022-08-12 | 開始されました | Piper Sandler | Overweight |
| 2021-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-01-29 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-11-18 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-12-11 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2019-11-08 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-11 | アップグレード | Gabelli & Co | Hold → Buy |
| 2019-07-29 | ダウングレード | Stifel | Buy → Hold |
| 2019-03-25 | アップグレード | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 繰り返されました | Stifel | Buy |
| 2018-02-23 | ダウングレード | Needham | Buy → Hold |
| 2018-02-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-03-01 | 繰り返されました | Wedbush | Outperform |
| 2016-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2016-08-05 | 繰り返されました | Wedbush | Outperform |
| 2016-08-02 | 開始されました | Citigroup | Buy |
| 2016-03-02 | 繰り返されました | Wedbush | Outperform |
| 2015-11-09 | 繰り返されました | Wedbush | Outperform |
| 2015-09-28 | アップグレード | Gabelli & Co | Sell → Hold |
| 2015-09-18 | ダウングレード | Gabelli & Co | Hold → Sell |
| 2015-08-10 | ダウングレード | JP Morgan | Overweight → Neutral |
すべてを表示
Lexicon Pharmaceuticals Inc (LXRX) 最新ニュース
Lexicon Pharmaceuticals (LXRX) reports break-even earnings for Q1 - MSN
Is Lexicon Pharmaceuticals, Inc. (LXRX) A Good Stock To Buy Now? - Insider Monkey
Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global DrugmakerNews and Statistics - IndexBox
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? - Yahoo Finance
LXRX News | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into common stock holdings - Stock Titan
Diane E. Sullivan converts 89,312 RSUs at Lexicon Pharmaceuticals (LXRX) - Stock Titan
[Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Lexicon Pharmaceuticals (LXRX) director exercises 89,312 RSUs into shares - Stock Titan
Lexicon Pharmaceuticals (LXRX) director converts 89,312 RSUs into 213,771-share stake - Stock Titan
Lexicon (NASDAQ: LXRX) director converts 89,312 restricted stock units into common stock - Stock Titan
Lexicon (NASDAQ: LXRX) director converts 89,312 RSUs into common stock, boosts stake - Stock Titan
LXRX: Pivotal HCM trial nears completion as pipeline and partnerships drive transformation - TradingView
How The Lexicon Pharmaceuticals (LXRX) Investment Narrative Is Evolving With Quiet Analyst Updates - Yahoo Finance
New Type 1 diabetes drug data from Lexicon at ADA 2026 meeting - Stock Titan
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions - The Manila Times
LXRX Stock Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Lexicon (LXRX) Q1 2026 Earnings Transcript - The Globe and Mail
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
Lexicon Pharma schedules Jefferies healthcare fireside chat for June 4 - Stock Titan
SA analyst upgrades/downgrades: SMCI, AMZN, SFM, LXRX - Seeking Alpha
Lexicon Pharmaceuticals: Uncertainty Clouds The Bull Case (Rating Downgrade) (NASDAQ:LXRX) - Seeking Alpha
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX) - Insider Monkey
LXRX Stock Price, Quote & Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? - Eastern Progress
5 Best Penny Stocks to Buy for Long Term - Insider Monkey
Lexicon anticipates SONATA-HCM enrollment completion by mid-2026 while highlighting $100m Hercules debt facility - MSN
A Look At Lexicon Pharmaceuticals (LXRX) Valuation After Improved Q1 Revenue And Narrowed Net Loss - Sahm
Lexicon Pharmaceuticals: up to 50 percent of type 2 diabetes patients affected by painful neuropathy - Traders Union
Lexicon Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-05-15 - Seeking Alpha
Navigating Life with Hypertrophic Cardiomyopathy - GlobeNewswire Inc.
Lexicon Pharmaceuticals (LXRX) Is Up 52.5% After Q1 Loss Narrows And Revenue JumpsHas The Bull Case Changed? - simplywall.st
Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's Changed - Yahoo Finance
Lexicon Pharmaceuticals management to join Nasdaq HQ fireside chat - Traders Union
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - Herald and News
Fireside chat at Nasdaq HQ: Lexicon joins H.C. Wainwright investor event May 19 - Stock Titan
LXRX Maintained by Citigroup -- Price Target Raised to $3.10 - GuruFocus
$Lexicon Pharmaceuticals (LXRX.US)$ 🚀🚀🚀🚀🚀🤩🤩🤩🤩🤩 - Moomoo
Citigroup Issues Positive Forecast for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price - MarketBeat
Citi Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Raises Target Price to $3.1 - Moomoo
Lexicon (LXRX) Reports $21.1M Q1 Revenue Driven by Novo Nordisk Milestones - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) 財務データ
収益
当期純利益
現金流量
EPS
Lexicon Pharmaceuticals Inc (LXRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
126,122 |
| SOBECKI CHRISTOPHER J | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
293,177 |
| Cheung Ivan | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
89,312 |
| BARKER SAM L | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
213,771 |
| Amouyal Philippe | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
374,486 |
| DEBBANE RAYMOND | Director |
Jun 03 '26 |
Option Exercise |
0.00 |
89,312 |
0 |
1,995,498 |
| Artal Participations S.a r.l. | Director |
Apr 30 '26 |
Option Exercise |
0.00 |
20,421,735 |
0 |
175,156,062 |
| DEBBANE RAYMOND | Director |
Feb 25 '26 |
Buy |
1.49 |
2,000 |
2,980 |
1,906,186 |
| DEBBANE RAYMOND | Director |
Feb 23 '26 |
Buy |
1.47 |
100,000 |
147,000 |
1,904,186 |
| DEBBANE RAYMOND | Director |
Feb 20 '26 |
Buy |
1.48 |
100,000 |
147,790 |
1,804,186 |
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):